
May 2026
π£ VC round data is live. Check it out!
![]() | Lonza Group is a contract development and manufacturing organization. It operates under four segments: small molecules, biologics, cell and gene, and capsules and health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides development and manufacturing services throughout the entire lifecycle of a product, from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations. | $639 | -12% | $45B | $49B | 5.8x | 18.4x | ||
![]() | Siegfried is a global contract development and manufacturing organization. It derives its revenue primarily from long-term supply agreements with biotechnology and pharmaceutical customers. Siegfried develops and manufactures active pharmaceutical ingredients, finished dosage forms (tablets, capsules, sterile vials, ampules, cartridges, and ointments), and viral vectors. The company provides these services throughout the entire drug lifecycle, including chemical and analytical development, pilot manufacturing, and commercial-scale manufacturing. Siegfried has a large global footprint with 13 production sites on three continents. | $104 | -15% | $5B | $4B | 2.6x | 11.0x | ||
![]() | PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia. | $48 | +78% | $2B | $2B | 3.6x | 32.2x | ||
| Median | $104 | -12% | $5B | $4B | 3.6x | 18.4x |
Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.